LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want access to our free earnings report on HealthEquity, Inc. (NASDAQ: HQY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=HQY. The Company reported its financial results on June 04, 2018, for the first quarter of the fiscal year 2019, ended April 30, 2018. The Company surpassed analysts' estimates for earnings and revenues in Q1 FY19. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, HealthEquity most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Earnings Highlights and Summary
For Q1 FY19, HealthEquity's total revenues reached $69.90 million, an increase of 26.13% from $55.42 million in Q1 FY18. The Company's revenue numbers exceeded analysts' consensus estimates of $68.80 million.
For the quarter under review, HealthEquity's service revenues increased 10.38% to $24.82 million; its custodial revenues jumped 47.18% to $28.43 million on a y-o-y basis; and its interchange revenues advanced 22.28% to $16.65 million on a y-o-y basis. HealthEquity had HSA Members of 3.50 million in Q1 FY19, an increase of 24% from Q1 FY18. The Company had custodial assets of $6.90 billion in the reported quarter, an increase of 31% from the prior year's same quarter.
During Q1 FY19, HealthEquity's total cost of revenues was $25.55 million, 17.84% higher than $21.68 million in Q1 FY18. The Company's gross profit advanced 31.46% to $44.36 million in the quarter under review from $33.74 million in the year ago comparable quarter.
HealthEquity incurred total operating expenses of $23.82 million in Q1 FY19, 33.69% higher than $17.81 million in Q1 FY18. For the reported quarter, the Company's sales and marketing (S&M) expenses increased 48.45% to $6.86 million on a y-o-y basis; its technology and development expenses jumped 27.83% to $7.98 million on a y-o-y basis; while its general and administrative (G&A) expenses advanced 27.93% to $7.51 million on a y-o-y basis. HealthEquity's income from operations was $20.54 million in Q1 FY19, an increase of 28.96% from $15.93 million in Q1 FY18. Besides, the Company's adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) advanced 32.16% to $29.63 million in the reported quarter from $22.42 million in the previous year's corresponding quarter.
HealthEquity had a net income of $22.58 million in the quarter ended April 30, 2018, up 60.93% from $14.03 million in Q1 FY18. The Company's diluted earnings per share (EPS) also ascended 56.52% to $0.36 in the reported quarter from $0.23 in the year ago same quarter. The Company's reported earnings included stock-based compensation and excess tax benefit due to the adoption of ASU 2016-09. HealthEquity's adjusted diluted EPS, excluding these non-recurring items, were $0.31 in Q1 FY19, up 63.16% from $0.19 in Q1 FY18. This was higher than analysts' consensus estimates of $0.28 per share.
HealthEquity had cash, cash equivalents, and marketable securities of $269.84 million as on April 30, 2018, an increase of 12.31% from $240.27 million as on January 31, 2018. The Company had no outstanding debt as on April 30, 2018, the same as on January 31, 2018.
HealthEquity's cash provided by operating activities was $22.70 million in the three months ended April 30, 2018, 45.76% higher than $15.58 million in the comparable period of last year.
HealthEquity spent $1.12 million on purchases of property and equipment in Q1 FY19, 21.99% lower than $1.44 million in Q1 FY18. The Company generated $10.17 million from the exercise of common stock options in the reported quarter compared to $3.83 million in Q1 FY18, reflecting an increase of 165.53%.
HealthEquity increased its outlook for the full fiscal year 2019, ending January 31, 2019. The Company expects its revenues to be between $278 million and $284 million, and its net income to be between $55 million to $59 million for FY19. The Company expects its GAAP diluted EPS to be in the range of $0.86 to $0.92, and its adjusted EBITDA to be in the band of $107 million to $111 million for FY19. HealthEquity expects its non-GAAP net income to be in the range of $64 million and $68 million, and its non-GAAP diluted EPS to be in the band of $1 to $1.06 for FY19.
Stock Performance Snapshot
June 29, 2018 - At Friday's closing bell, HealthEquity's stock dropped 2.53%, ending the trading session at $75.10.
Volume traded for the day: 450.39 thousand shares.
Stock performance in the last month – up 1.06%; previous three-month period – up 24.36%; past twelve-month period – up 51.53%; and year-to-date – up 60.95%
After last Friday's close, HealthEquity's market cap was at $4.60 billion.
Price to Earnings (P/E) ratio was at 83.63.
The stock is part of the Technology sector, categorized under the Healthcare Information Services industry. This sector was up 0.2% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.